Erratum to: Diabetes Ther (2015) 6:317–328 DOI: 10.1007/s13300-015-0119-x
The authors wish to make corrections to the article.
The third sentence of the “Patient Disposition and Demographics” subsection within the “Results” section should read:
“For metformin and sulfonylurea, 72% and 74% of patients also had HbA1c assessed at week 52.”
The third paragraph of the “Predictive Parameters” subsection within the “Results” section should read:
“The predictive parameters for improvements in HbA1c for week 24, based on the composite unified early-response measure (reduction in HbA1c level of ≥1.0% or HbA1c level of <7.0%) for metformin were 0.83, 0.81, 0.44, and 0.96; for sulfonylurea, 0.79, 0.94, 0.71, and 0.96; and for insulin glargine, 0.67, 0.89, 0.65, and 0.90.”
Within the footnote to Table 5, the optimal early-response measure should be defined as:
“HbA1c reduction of ≥1.0% for sulfonylurea and glargine at week 24 and for sulfonylurea at week 52, HbA1c reduction of ≥0.8% for metformin at week 24, and HbA1c reduction of ≥0.6% for metformin at week 52”.
Open Access
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Footnotes
The online version of the original article can be found under doi:10.1007/s13300-015-0119-x.